A LEADING EDGE IN THE IMMUNO-ONCOLOGY MARKET

Despite all efforts in CANCER PREVENTION and significant progress achieved in the availability of NEW TREATMENT OPTIONS for patients in the last decade, incidences and global mortality rates are projected to continue to rise. Response rates for available drugs depend on a variety of factors but often do not exceed 30 %. Moreover, many patients relapse and the cancer cells evolve further. For many patients, there are still no effective and safe treatment options available leading to a huge unmet medical need.

invIOs offers unique and highly promising new treatment options in the INNOVATIVE THERAPY area of IMMUNO-ONCOLOGY. We are pioneers in research & development of drug candidates in CELL THERAPIES targeting new immune checkpoints and in Immunomodulation.

OUR SUCCESS IS BASED ON THREE DISTINCTIVE PILLARS

#CellTherapyPlatform for solid (and liquid) cancers

#SmallMolecule IO Project

#InnovationHub for growth

OUR INNOVATIVE IMMUNO-ONCOLOGY PIPELINE

APN401

is a #TUMOR-REACTIVE, autologous cell therapy with a siRNA-based, highly specific activation of white blood cells. Currently undergoing clinical Phase 1 in patients with various solid tumors.

INV441

is a #TUMOR-ASSOCIATED, autologous cell therapy with a siRNA-based, highly specific activation of local immune cells, Tumor Infiltrating Lymphocytes (#TILs). Currently in early pre-clinical stage.

INV501

is a #TUMOR-SPECIFIC immune activating novel small molecule in pre-clinical development for immune activation upon oral application.

WE ARE HIRING

Making a HUGE IMPACT on patient’s lives keeps us motivated. At invIOs, we  are making a contribution to PEOPLE’S WELLBEING. We strive every day to improve the lives of our patients with next-generation technologies and individual therapies.

When working at invIOs you could contribute to solving some of the toughest challenges in treating cancer on a daily basis. We at invIOs think that our people are our most important asset.